OTC: JWCTF - JW (Cayman) Therapeutics Co. Ltd

Rentabilidade por seis meses: -43.16%
Setor: Healthcare

Cronograma de promoção JW (Cayman) Therapeutics Co. Ltd

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.

mais detalhes
The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

EBITDA -0.3143
EV/EBITDA 0.5634
Industry Biotechnology
P/BV 1.82
P/S 164.53
Sector Health Care
Валюта usd
Валюта отчета cny
Выручка 0.0055
Сайт https://www.jwtherapeutics.com
Цена ао 0.255
Число акций ао 0.41153 млрд
Alteração de preço por dia: +0.3717% (0.1614)
Alteração de preço por semana: -4.59% (0.1698)
Alteração de preço por mês: -36.47% (0.255)
Alteração de preço em 3 meses: -20.59% (0.204)
Mudança de preço em seis meses: -43.16% (0.285)
Mudança de preço por ano: -39.37% (0.2672)
Mudança de preço em 3 anos: -88.98% (1.47)
Mudança de preço em 5 anos: -0% (0.162)
Mudança de preço em 10 anos: -0% (0.162)
Mudança de preço desde o início do ano: -4.59% (0.1698)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 4.52 3
P/BV 0.4665 10
P/E 0 0
EV/EBITDA -0.2077 0
Total: 5.38

Eficiência

Nome Significado Nota
ROA, % -35.79 0
ROE, % -45.61 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.588 10
Total: 9.6

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 3070.82 10
Rentabilidade Ebitda, % 108.61 10
Rentabilidade EPS, % 9.47 2
Total: 6.2
Mais detalhes

Instituições Volume Compartilhar, %
DFA Emerging Markets Small Cap Series 467500 0.11
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 336309 0.08
DFA Emerging Markets Core Equity Portfolio 98500 0.02
Dimensional ETF Tr-Dimensional Emerging Markets Core Equity 2 ETF 95500 0.02
SPDR (R) Idx Shares-SPDR (R) S&P (R) China ETF 76500 0.02
Dimensional ETF Tr-Dimensional World ex U.S. Core Equity 2 ETF 69500 0.02
DFA Investment Dimensions-World Ex U.S. Core Equity Port 55500 0.01
SPDR (R) Idx Shares-SPDR (R) Emerging Markets Small Cap ETF 42350 0.01
DFA Investment Dimensions-DFA Emerging Markets Targeted Value Port 38000 0.01
Avantis Emerging Markets Equity ETF 36000 0.01



Supervisor Cargo Pagamento Ano de nascimento
Dr. Yiping Li M.D. Co-Founder & Interim Chairman 836.74k 1964 (61 ano)
Cao Xiaoping Ph.D. Senior Vice President of Tech Operations N/A
Dr. Shaun Paul Cordoba Ph.D. Senior VP & Chief Scientific Officer N/A 1980 (45 anos)
Mr. Raymond J. Hage Jr. Senior Vice President of Corporate Development N/A 1968 (57 anos)
Mr. Mark J. Gilbert M.D. Senior Advisor & Acting Chief Medical Officer N/A
Ms. Ka Man Ng A.C.I.S., A.C.S. Company Secretary N/A 1978 (47 anos)
Mr. Qiang Ma Senior VP & Chief Commercial Officer N/A 1978 (47 anos)
Ms. Yun Qin Senior Vice President of Clinical Sciences & Medical Services N/A 1982 (43 ano)
Dr. Su Yang Senior Vice President Of Clinical Research & PMO N/A 1979 (46 anos)
Mr. Min Liu CEO & Executive Director 1973 (52 ano)

Endereço: China, Shanghai, Building B - abrir no Google Maps, abrir mapas Yandex
Site: https://www.jwtherapeutics.com